Skip to main content
4D Molecular Therapeutics, Inc. logo

4D Molecular Therapeutics, Inc. — Investor Relations & Filings

Ticker · FDMT ISIN · US35104E1001 US Manufacturing
Open in API
Filings indexed 372 across all filing types
Latest filing 2022-08-23 Capital/Financing Update
Country US United States of America
Listing US FDMT

About 4D Molecular Therapeutics, Inc.

https://4dmoleculartherapeutics.com/

4D Molecular Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on inventing and developing genetic medicines to treat large-market diseases with unmet medical needs. The company utilizes its proprietary Therapeutic Vector Evolution platform, which harnesses the power of directed evolution, to create customized and optimized adeno-associated virus (AAV) vectors. These engineered vectors are designed for targeted delivery and enhanced therapeutic efficacy. 4DMT's clinical pipeline is concentrated on developing transformative products for serious conditions in ophthalmology, such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), and in pulmonology, including cystic fibrosis.

Recent filings

Filing Released Lang Actions
S-3
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used for registering securities for sale to the public. It includes a prospectus for resale of shares by selling stockholders, details about the offering, and references to other SEC filings such as 10-K, 10-Q, and proxy statements. The document is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to securities registration and offering. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length is substantial (15,000 characters), and it contains detailed registration and offering information, not just an announcement or notice, so it is not RPA or RNS. Therefore, the correct classification is CAP with high confidence.
2022-08-23 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 11, 2022, reporting the company's financial results for the quarter ended June 30, 2022. It includes a press release titled '4D Molecular Therapeutics Reports Second Quarter 2022 Financial Results and Provides 4D-310 Program Update' as an exhibit. The document itself is relatively short (3220 characters) and primarily serves to announce the earnings release rather than containing detailed financial statements or analysis. According to the rules, initial announcements of quarterly financial results with key highlights only are classified as Earnings Release (ER).
2022-08-11 English
10-Q
Interim / Quarterly Report Q2 2022
2022-08-11 English
OWNERSHIP DOCUMENT
Director's Dealing
2022-06-27 English
FORM 4
Director's Dealing
2022-06-22 English
AMENDMENT NO. 1 TO SCHEDULE 13G
Major Shareholding Notification
2022-06-21 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.